Analysts forecast that DaVita HealthCare Partners Inc. (NYSE:DVA) will report earnings of $0.90 per share for the current quarter, Zacks reports. Five analysts have made estimates for DaVita HealthCare Partners’ earnings. The lowest EPS estimate is $0.87 and the highest is $0.94. DaVita HealthCare Partners reported earnings per share of $1.01 in the same quarter last year, which indicates a negative year-over-year growth rate of 10.9%. The firm is scheduled to announce its next earnings report after the market closes on Tuesday, August 1st.
On average, analysts expect that DaVita HealthCare Partners will report full-year earnings of $3.49 per share for the current fiscal year, with EPS estimates ranging from $3.34 to $3.57. For the next financial year, analysts forecast that the firm will post earnings of $3.81 per share, with EPS estimates ranging from $3.53 to $4.14. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that follow DaVita HealthCare Partners.
DaVita HealthCare Partners (NYSE:DVA) last issued its quarterly earnings data on Tuesday, May 2nd. The company reported $0.79 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.82 by $0.03. DaVita HealthCare Partners had a net margin of 8.28% and a return on equity of 14.85%. The firm had revenue of $3.70 billion during the quarter, compared to analyst estimates of $3.69 billion.
Several research firms recently weighed in on DVA. BidaskClub cut DaVita HealthCare Partners from a “hold” rating to a “sell” rating in a report on Saturday, July 8th. Jefferies Group LLC set a $70.00 price target on DaVita HealthCare Partners and gave the stock a “buy” rating in a report on Friday, May 26th. Zacks Investment Research cut DaVita HealthCare Partners from a “hold” rating to a “sell” rating in a report on Tuesday, July 4th. TheStreet upgraded DaVita HealthCare Partners from a “c+” rating to a “b-” rating in a research note on Monday, April 3rd. Finally, Goldman Sachs Group, Inc. (The) restated a “sell” rating and set a $62.00 price objective on shares of DaVita HealthCare Partners in a research note on Thursday, May 25th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and two have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $69.50.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://www.com-unik.info/2017/08/12/davita-healthcare-partners-inc-dva-expected-to-post-earnings-of-0-90-per-share-updated-updated-updated.html.
In other DaVita HealthCare Partners news, Director William L. Roper sold 12,994 shares of DaVita HealthCare Partners stock in a transaction dated Thursday, May 4th. The stock was sold at an average price of $65.89, for a total transaction of $856,174.66. Following the transaction, the director now directly owns 45,277 shares of the company’s stock, valued at approximately $2,983,301.53. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Javier Rodriguez sold 1,294 shares of DaVita HealthCare Partners stock in a transaction dated Monday, May 15th. The stock was sold at an average price of $66.21, for a total value of $85,675.74. Following the transaction, the chief executive officer now directly owns 99,111 shares in the company, valued at $6,562,139.31. The disclosure for this sale can be found here. In the last three months, insiders have sold 22,702 shares of company stock worth $1,495,492. 2.00% of the stock is currently owned by company insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the company. SRS Capital Advisors Inc. increased its position in shares of DaVita HealthCare Partners by 6.6% in the first quarter. SRS Capital Advisors Inc. now owns 1,966 shares of the company’s stock valued at $133,000 after buying an additional 122 shares during the last quarter. Raymond James Trust N.A. acquired a new position in shares of DaVita HealthCare Partners during the first quarter worth about $202,000. Advisor Partners LLC acquired a new position in shares of DaVita HealthCare Partners during the first quarter worth about $218,000. Wetherby Asset Management Inc. increased its position in shares of DaVita HealthCare Partners by 3.3% in the first quarter. Wetherby Asset Management Inc. now owns 3,224 shares of the company’s stock worth $219,000 after buying an additional 104 shares in the last quarter. Finally, Pacer Advisors Inc. increased its position in shares of DaVita HealthCare Partners by 3.0% in the first quarter. Pacer Advisors Inc. now owns 3,422 shares of the company’s stock worth $233,000 after buying an additional 101 shares in the last quarter. 81.93% of the stock is currently owned by hedge funds and other institutional investors.
Shares of DaVita HealthCare Partners (DVA) traded up 0.88% during mid-day trading on Monday, reaching $65.27. 1,382,083 shares of the company’s stock traded hands. The firm has a 50-day moving average price of $65.13 and a 200-day moving average price of $66.08. The company has a market capitalization of $12.70 billion, a P/E ratio of 10.72 and a beta of 0.89. DaVita HealthCare Partners has a 1-year low of $54.50 and a 1-year high of $78.40.
About DaVita HealthCare Partners
DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about DaVita HealthCare Partners Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for DaVita HealthCare Partners Inc. and related companies.